Resveratrol doesn't improve insulin sensitivity

Resveratrol doesn't improve insulin sensitivity

(HealthDay)—Resveratrol supplementation does not improve hepatic or peripheral insulin sensitivity among patients with type 2 diabetes, according to a study published online Oct. 7 in Diabetes Care.

Silvie Timmers, Ph.D., from Maastricht University in the Netherlands, and colleagues treated 17 subjects with well-controlled type 2 diabetes with placebo and 150 mg/day resveratrol in a randomized double-blind crossover study for 30 days.

The researchers found that hepatic and peripheral insulin sensitivity were not affected by resveratrol treatment. Resveratrol similarly did not affect intrahepatic lipid content, although the change in intrahepatic lipid content correlated negatively with plasma resveratrol levels. Resveratrol was also found to significantly improve ex vivo mitochondrial function.

"Our results question the generalized value of resveratrol as add-on therapy in the treatment of type 2 diabetes and emphasize the need to perform studies in drug-naive patients with type 2 diabetes or subjects with prediabetes," the authors write.

One author was employed by DSM Nutritional Products, which supplied the resveratrol and placebo capsules and performed the resveratrol and dihydroresveratrol analysis.

Explore further

Resveratrol can help correct hormone imbalance in women with PCOS

More information: Full Text (subscription or payment may be required)
Journal information: Diabetes Care

Copyright © 2016 HealthDay. All rights reserved.

Citation: Resveratrol doesn't improve insulin sensitivity (2016, October 24) retrieved 20 June 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments